2014
DOI: 10.3892/or.2014.3257
|View full text |Cite
|
Sign up to set email alerts
|

Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug

Abstract: Cellular resistance to platinum anticancer compounds is governed by no less than two molecular processes; DNA repair and cellular accumulation of drug. Gli1 is an upstream regulator of nucleotide excision repair, effecting this process through c-jun. We, therefore, investigated whether Gli1 plays a role in cellular accumulation of cisplatin. Using a Gli1-specific shRNA, we explored the role of Gli1 in the cellular accumulation and efflux of cisplatin, in cisplatin-resistant A2780-CP70 human ovarian cancer cell… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
24
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(25 citation statements)
references
References 26 publications
1
24
0
Order By: Relevance
“…of proteins that is required for drug efflux (39). Amable et al showed that Gli1 plays a role in the cellular accumulation of cisplatin through the regulation of multiple transport proteins including octamer-binding protein (OCT)1, OCT2, OCT3, the copper transporter CTR1 and the ATPase copper transporter ATP7B (40). On the other hand, cisplatin, in turn, affects the Hh pathway.…”
Section: Discussionmentioning
confidence: 99%
“…of proteins that is required for drug efflux (39). Amable et al showed that Gli1 plays a role in the cellular accumulation of cisplatin through the regulation of multiple transport proteins including octamer-binding protein (OCT)1, OCT2, OCT3, the copper transporter CTR1 and the ATPase copper transporter ATP7B (40). On the other hand, cisplatin, in turn, affects the Hh pathway.…”
Section: Discussionmentioning
confidence: 99%
“…GLI1 also plays a pivotal role in cellular accumulation of cisplatin in cisplatin-resistant A2780-CP70 human ovarian cancer cells (Amable et al , 2014). Pretreatment of the cisplatin-resistant human ovarian cancer cell line A2780-CP70 with anti-GLI1 shRNA resulted in supra-additive cell killing with cisplatin.…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, in Hh driven cancers, the therapies of Gli inhibitors are often reported to be related to drug resistance (44,45). However, the underlying mechanism is unclear.…”
Section: Discussionmentioning
confidence: 99%